Scavidin

Scavidin is a recombinant, soluble version of the human scavenger receptor CD163, developed by Scancell. Originally engineered as a therapeutic intervention for severe COVID-19, it was designed to bind and neutralize the SARS-CoV-2 spike protein, thereby preventing viral entry and the subsequent hyper-inflammatory response known as a cytokine storm. Beyond its antiviral potential, Scavidin mimics the natural scavenger functions of CD163 by binding to and clearing pro-inflammatory mediators such as hemoglobin-haptoglobin complexes. This mechanism makes it a candidate for treating other systemic inflammatory conditions, including sepsis and cytokine release syndrome, where it acts as a decoy receptor to dampen overactive immune responses and prevent organ damage. The protein was developed using Scancell's proprietary AvidiMab platform to enhance its binding avidity and therapeutic efficacy.

Other names

Soluble CD163sCD163sCD-163sCD 163